Junling Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Junling Xu has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
Chang Fu
Department of Nuclear Medicine, Zhengzhou University People's Hospital (Henan Provincial People's Hospital), Zhengzhou 450003, China
4 shared publicationsHuiqiang Li
Department of Nuclear Medicine, Henan Key Laboratory of Novel Molecular Probes and Clinical Translation in Nuclear Medicine, Henan Provincial People's Hospital & the People's Hospital of Zhengzhou University, Zhengzhou, 450003, China
3 shared publications- Jie-Wen Zhang
Department of Neurology, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, China
2 shared publications Jing-Yu Shao
Department of Neurology, Zhengzhou University People's Hospital (Henan Provincial People's Hospital), Zhengzhou 450003, China
2 shared publicationsLi Wang
Henan Academy of Medical Sciences, Zhengzhou 450003, China
2 shared publicationsWeifeng Zhang
Department of Nuclear Medicine, Henan Key Laboratory of Novel Molecular Probes and Clinical Translation in Nuclear Medicine, Henan Provincial People's Hospital & the People's Hospital of Zhengzhou University, Zhengzhou 450003, China
2 shared publications
Latest Publications
- Open Access
- 5 June 2026
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 13 (7) , 100613
Diagnostic performance of an automated plasma p-tau217 chemiluminescent assay for detecting Aβ pathology in a Chinese memory clinic cohort
- 5 June 2026
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 13 (7) , 100613
Open AccessDiagnostic performance of an automated plasma p-tau217 chemiluminescent assay for detecting Aβ pathology in a Chinese memory clinic cohort
- Open Access
- 1 March 2025
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 15 (3) , 2029-2041
Assessment of coronary computed tomography angiography-derived plaque features in the diagnosis of optical coherence tomography-defined vulnerable plaques
Background: Identification of vulnerable plaque is essential for pre-estimation of the risk of cardiovascular disease (CVD) and stratification of major adverse cardiac events (MACEs) risks. This study aimed to evaluate the diagnostic ability of coronary computed tomography angiography (CCTA)-derived qualitative and quantitative plaque features in detecting optical coherence tomography (OCT)-defined vulnerable plaques. Methods: A total of 31 patients who underwent both CCTA and OCT were retrospectively included in this study. The results of OCT and CCTA were blindly analyzed on a segment-to-segment comparison. The qualitative and quantitative plaque parameters derived by CCTA were recorded. Univariate analysis and multivariate logistic regression analysis were performed to reveal the independent predictors. The diagnostic efficacy of quantitative parameters was evaluated by receiver operating characteristic (ROC) curve and area under the curve (AUC). Results: A total of 76 plaques in 31 patients were included for analysis, of which 15/76 plaques (19.7%, 10 patients) were vulnerable plaques. Low-density plaques, spotty calcification (SC), positive remodeling (PR), number of high-risk plaque signs, non-calcified fraction, and lipid fraction displayed significant differences between vulnerable and non-vulnerable plaques (PConclusions: The CCTA-derived plaque characteristics were able to detect the OCT-defined vulnerable plaques and show great potential as a non-invasive biomarker for early diagnosis of coronary vulnerable plaques.
- 1 March 2025
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 15 (3) , 2029-2041
Open AccessAssessment of coronary computed tomography angiography-derived plaque features in the diagnosis of optical coherence tomography-defined vulnerable plaques
Background: Identification of vulnerable plaque is essential for pre-estimation of the risk of cardiovascular disease (CVD) and stratification of major adverse cardiac events (MACEs) risks. This study aimed to evaluate the diagnostic ability of coronary computed tomography angiography (CCTA)-derived qualitative and quantitative plaque features in detecting optical coherence tomography (OCT)-defined vulnerable plaques. Methods: A total of 31 patients who underwent both CCTA and OCT were retrospectively included in this study. The results of OCT and CCTA were blindly analyzed on a segment-to-segment comparison. The qualitative and quantitative plaque parameters derived by CCTA were recorded. Univariate analysis and multivariate logistic regression analysis were performed to reveal the independent predictors. The diagnostic efficacy of quantitative parameters was evaluated by receiver operating characteristic (ROC) curve and area under the curve (AUC). Results: A total of 76 plaques in 31 patients were included for analysis, of which 15/76 plaques (19.7%, 10 patients) were vulnerable plaques. Low-density plaques, spotty calcification (SC), positive remodeling (PR), number of high-risk plaque signs, non-calcified fraction, and lipid fraction displayed significant differences between vulnerable and non-vulnerable plaques (PConclusions: The CCTA-derived plaque characteristics were able to detect the OCT-defined vulnerable plaques and show great potential as a non-invasive biomarker for early diagnosis of coronary vulnerable plaques.
- 2 December 2024
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 50 (2) , 176-178
Multitracer PET/CT Findings in a Case of Behavioral Variant Frontotemporal Dementia With Parkinsonism
S: We report the clinical and multimodal PET/CT manifestations in a patient with behavioral variant frontotemporal dementia and parkinsonism. The 18F-FDG PET scan revealed hypometabolism in the left supratentorial cortex. The 18F-fluorodopa PET scan demonstrated decreased uptake in the bilateral striatum, most prominent in the head of caudate nucleus. The 18F-florbetapir PET scan indicated an absence of β-amyloid deposition, whereas the 18F-flortaucipir PET scan showed uptake in the left hemisphere neocortex. The clinical presentation and asymmetric neuroimaging features supported the underlying frontotemporal lobar degeneration-tau pathology.
- 2 December 2024
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 50 (2) , 176-178
Multitracer PET/CT Findings in a Case of Behavioral Variant Frontotemporal Dementia With Parkinsonism
S: We report the clinical and multimodal PET/CT manifestations in a patient with behavioral variant frontotemporal dementia and parkinsonism. The 18F-FDG PET scan revealed hypometabolism in the left supratentorial cortex. The 18F-fluorodopa PET scan demonstrated decreased uptake in the bilateral striatum, most prominent in the head of caudate nucleus. The 18F-florbetapir PET scan indicated an absence of β-amyloid deposition, whereas the 18F-flortaucipir PET scan showed uptake in the left hemisphere neocortex. The clinical presentation and asymmetric neuroimaging features supported the underlying frontotemporal lobar degeneration-tau pathology.
- 18 April 2024
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 35 (5) , 567-574
18F-Radiolabeling and Evaluation of an AMD3465 Derivative for PET Imaging of CXCR4 in a Mouse Breast Tumor Model
The exploration of pharmaceutically active agents and positron emission tomography (PET) tracers targeting CXCR4 has been a focal point in cancer research given its pivotal role in the development and progression of various cancers. While significant strides have been made in PET imaging with radiometal-labeled tracers, the landscape of F-18-labeled small molecule tracers remains relatively limited. Herein, we introduce a novel and promising derivative, [F-18]SFB-AMD3465, as a targeted PET tracer for CXCR4. The compound was synthesized by modifying the pyridine ring of AMD3465, which was subsequently labeled with F-18 using [F-18]SFB. The study provides comprehensive insights into the design, synthesis, and biological evaluation of [F-18]SFB-AMD3465. In vitro and in vivo assessments demonstrated the CXCR4-dependent, specific, and sensitive uptake of [F-18]SFB-AMD3465 in the CXCR4-overexpressing 4T1 cell line and the corresponding xenograft-bearing mouse model. These findings contribute to bridging the gap in F-18-labeled PET tracers for CXCR4 and underscore the potential of [F-18]SFB-AMD3465 as a PET radiotracer for in vivo CXCR4 imaging.
- 18 April 2024
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 35 (5) , 567-574
18F-Radiolabeling and Evaluation of an AMD3465 Derivative for PET Imaging of CXCR4 in a Mouse Breast Tumor Model
The exploration of pharmaceutically active agents and positron emission tomography (PET) tracers targeting CXCR4 has been a focal point in cancer research given its pivotal role in the development and progression of various cancers. While significant strides have been made in PET imaging with radiometal-labeled tracers, the landscape of F-18-labeled small molecule tracers remains relatively limited. Herein, we introduce a novel and promising derivative, [F-18]SFB-AMD3465, as a targeted PET tracer for CXCR4. The compound was synthesized by modifying the pyridine ring of AMD3465, which was subsequently labeled with F-18 using [F-18]SFB. The study provides comprehensive insights into the design, synthesis, and biological evaluation of [F-18]SFB-AMD3465. In vitro and in vivo assessments demonstrated the CXCR4-dependent, specific, and sensitive uptake of [F-18]SFB-AMD3465 in the CXCR4-overexpressing 4T1 cell line and the corresponding xenograft-bearing mouse model. These findings contribute to bridging the gap in F-18-labeled PET tracers for CXCR4 and underscore the potential of [F-18]SFB-AMD3465 as a PET radiotracer for in vivo CXCR4 imaging.
- 16 July 2023
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 124-125, 108364
Integrin αvβ3 and EGFR dual-targeted [64Cu]Cu-NOTA-RGD-GE11 heterodimer for PET imaging in pancreatic cancer mouse model
- 16 July 2023
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 124-125, 108364
Integrin αvβ3 and EGFR dual-targeted [64Cu]Cu-NOTA-RGD-GE11 heterodimer for PET imaging in pancreatic cancer mouse model
- Open Access
- 3 July 2023
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 10, 1180541
Delayed 18F-FDG PET imaging provides better metabolic asymmetry in potential epileptogenic zone in temporal lobe epilepsy
Objective: To investigate the value of 18F-FDG positron emission tomography/computed tomography (PET/CT) two time point imaging for the identification of the potential epileptogenic zone (EZ) in temporal lobe epilepsy (TLE).Methods: Fifty-two patients with TLE were prospectively enrolled in the 18F-FDG PET/CT two time point imaging study. The early imaging was obtained approximately 40 min (43.44 ± 18.04 min) after 18F-FDG injection, and the delayed imaging was obtained about 2 to 3 h (160.46 ± 28.70 min) after the injection. Visual and semi-quantitative analysis of 18F-FDG uptake were performed at the two time points in EZ and contralateral symmetrical region. The mean standardized uptake value (SUVmean) of EZ and contralateral symmetrical region was calculated to determine the asymmetry index (AI) of the early and delayed images, as well as in the MRI positive and negative patient groups.Results: Semi-quantitative analysis demonstrated that AI of the early and delayed 18F-FDG PET/CT images was 13.47 ± 6.10 and 16.43 ± 6.66, respectively. The ΔAI was 2.95 ± 3.05 in 52 TLE patients between the two time points. The AI of the EZ was significantly elevated in delayed images compared to the early images (p < 0.001). The AI of delayed imaging was also significantly elevated compared to the early imaging in both MRI positive (ΔAI = 2.81 ± 2.54, p < 0.001) and MRI negative (ΔAI = 3.21 ± 3.91, p < 0.003) groups, and more pronounced in MRI negative group. Visual analysis also showed that the delayed imaging appeared to be superior to the early imaging for identification of potential EZ.Conclusion: Delayed 18F-FDG PET imaging provided significantly better than the early imaging in the identification of potential EZ, which can be valuable during epilepsy pre-surgical evaluation in patients with TLE.
- 3 July 2023
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 10, 1180541
Open AccessDelayed 18F-FDG PET imaging provides better metabolic asymmetry in potential epileptogenic zone in temporal lobe epilepsy
Objective: To investigate the value of 18F-FDG positron emission tomography/computed tomography (PET/CT) two time point imaging for the identification of the potential epileptogenic zone (EZ) in temporal lobe epilepsy (TLE).Methods: Fifty-two patients with TLE were prospectively enrolled in the 18F-FDG PET/CT two time point imaging study. The early imaging was obtained approximately 40 min (43.44 ± 18.04 min) after 18F-FDG injection, and the delayed imaging was obtained about 2 to 3 h (160.46 ± 28.70 min) after the injection. Visual and semi-quantitative analysis of 18F-FDG uptake were performed at the two time points in EZ and contralateral symmetrical region. The mean standardized uptake value (SUVmean) of EZ and contralateral symmetrical region was calculated to determine the asymmetry index (AI) of the early and delayed images, as well as in the MRI positive and negative patient groups.Results: Semi-quantitative analysis demonstrated that AI of the early and delayed 18F-FDG PET/CT images was 13.47 ± 6.10 and 16.43 ± 6.66, respectively. The ΔAI was 2.95 ± 3.05 in 52 TLE patients between the two time points. The AI of the EZ was significantly elevated in delayed images compared to the early images (p < 0.001). The AI of delayed imaging was also significantly elevated compared to the early imaging in both MRI positive (ΔAI = 2.81 ± 2.54, p < 0.001) and MRI negative (ΔAI = 3.21 ± 3.91, p < 0.003) groups, and more pronounced in MRI negative group. Visual analysis also showed that the delayed imaging appeared to be superior to the early imaging for identification of potential EZ.Conclusion: Delayed 18F-FDG PET imaging provided significantly better than the early imaging in the identification of potential EZ, which can be valuable during epilepsy pre-surgical evaluation in patients with TLE.
- 15 July 2020
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 47 (11) , 2703-2705
FDG PET/CT evaluation of a patient recovering from COVID-19
- 15 July 2020
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 47 (11) , 2703-2705
FDG PET/CT evaluation of a patient recovering from COVID-19
- Open Access
- 24 January 2020
- Published by Hindawi Limited in Computational and Mathematical Methods in Medicine
- Vol. 2020, 1-10
Multicenter Computer-Aided Diagnosis for Lymph Nodes Using Unsupervised Domain-Adaptation Networks Based on Cross-Domain Confounding Representations
To achieve the robust high-performance computer-aided diagnosis systems for lymph nodes, CT images may be typically collected from multicenter data, which cause the isolated performance of the model based on different data source centers. The variability adaptation problem of lymph node data which is related to the problem of domain adaptation in deep learning differs from the general domain adaptation problem because of the typically larger CT image size and more complex data distributions. Therefore, domain adaptation for this problem needs to consider the shared feature representation and even the conditioning information of each domain so that the adaptation network can capture significant discriminative representations in a domain-invariant space. This paper extracts domain-invariant features based on a cross-domain confounding representation and proposes a cycle-consistency learning framework to encourage the network to preserve class-conditioning information through cross-domain image translations. Compared with the performance of different domain adaptation methods, the accurate rate of our method achieves at least 4.4% points higher under multicenter lymph node data. The pixel-level cross-domain image mapping and the semantic-level cycle consistency provided a stable confounding representation with class-conditioning information to achieve effective domain adaptation under complex feature distribution.
- 24 January 2020
- Published by Hindawi Limited in Computational and Mathematical Methods in Medicine
- Vol. 2020, 1-10
Open AccessMulticenter Computer-Aided Diagnosis for Lymph Nodes Using Unsupervised Domain-Adaptation Networks Based on Cross-Domain Confounding Representations
To achieve the robust high-performance computer-aided diagnosis systems for lymph nodes, CT images may be typically collected from multicenter data, which cause the isolated performance of the model based on different data source centers. The variability adaptation problem of lymph node data which is related to the problem of domain adaptation in deep learning differs from the general domain adaptation problem because of the typically larger CT image size and more complex data distributions. Therefore, domain adaptation for this problem needs to consider the shared feature representation and even the conditioning information of each domain so that the adaptation network can capture significant discriminative representations in a domain-invariant space. This paper extracts domain-invariant features based on a cross-domain confounding representation and proposes a cycle-consistency learning framework to encourage the network to preserve class-conditioning information through cross-domain image translations. Compared with the performance of different domain adaptation methods, the accurate rate of our method achieves at least 4.4% points higher under multicenter lymph node data. The pixel-level cross-domain image mapping and the semantic-level cycle consistency provided a stable confounding representation with class-conditioning information to achieve effective domain adaptation under complex feature distribution.
- Open Access
- 1 December 2019
- Published by Wolters Kluwer Health in Medicine
- Vol. 98 (49) , e18214
Evaluating and monitoring bone marrow hypoplasia in adults with aplastic anemia via high-resolution iliac magnetic resonance imaging in the current era
The diagnosis and monitoring of aplastic anemia (AA) rely heavily on a complete blood count (CBC), and multiple-site bone marrow (BM) aspirations and biopsies. However, these approaches have certain limitations. We aimed to assess high-resolution magnetic resonance imaging (MRI) as a complementary approach for evaluating BM hypoplasia and monitoring treatment response in adults with AA in the current era. Twelve newly diagnosed AA patients and 12 sex- and age-matched healthy controls were enrolled in this study from January 2017 to August 2018. A bilateral iliac 3.0T MRI was used to collect data for each subject, and the signal intensity on the T1-weighted images (T1WIs) were expressed as a contrast-to-noise ratio (CNR). The MRI, CBC, and BM biopsy data were analyzed and compared. A qualitative analysis identified a significant difference in MRI signal characteristics between the AA group and the healthy control group. The clinical classifications of very severe aplastic anemia (VSAA) and severe aplastic anemia (SAA) corresponded to pattern I and pattern II on the MR images, respectively. However, this imaging classification did not correlate with the biopsy-based BM cellularity measure. A quantitative analysis showed a significantly higher signal intensity in AA patients than in controls. A within-group comparison revealed that more severe types of AA, based on the clinical classification, corresponded to stronger signals. Notably, MRI could detect treatment response earlier than CBC, regardless of whether there were improvements in hematopoiesis. MRI can be used to predict the therapeutic effects in patients with AA and is an important complementary tool for evaluating and monitoring BM hypoplasia.
- 1 December 2019
- Published by Wolters Kluwer Health in Medicine
- Vol. 98 (49) , e18214
Open AccessEvaluating and monitoring bone marrow hypoplasia in adults with aplastic anemia via high-resolution iliac magnetic resonance imaging in the current era
The diagnosis and monitoring of aplastic anemia (AA) rely heavily on a complete blood count (CBC), and multiple-site bone marrow (BM) aspirations and biopsies. However, these approaches have certain limitations. We aimed to assess high-resolution magnetic resonance imaging (MRI) as a complementary approach for evaluating BM hypoplasia and monitoring treatment response in adults with AA in the current era. Twelve newly diagnosed AA patients and 12 sex- and age-matched healthy controls were enrolled in this study from January 2017 to August 2018. A bilateral iliac 3.0T MRI was used to collect data for each subject, and the signal intensity on the T1-weighted images (T1WIs) were expressed as a contrast-to-noise ratio (CNR). The MRI, CBC, and BM biopsy data were analyzed and compared. A qualitative analysis identified a significant difference in MRI signal characteristics between the AA group and the healthy control group. The clinical classifications of very severe aplastic anemia (VSAA) and severe aplastic anemia (SAA) corresponded to pattern I and pattern II on the MR images, respectively. However, this imaging classification did not correlate with the biopsy-based BM cellularity measure. A quantitative analysis showed a significantly higher signal intensity in AA patients than in controls. A within-group comparison revealed that more severe types of AA, based on the clinical classification, corresponded to stronger signals. Notably, MRI could detect treatment response earlier than CBC, regardless of whether there were improvements in hematopoiesis. MRI can be used to predict the therapeutic effects in patients with AA and is an important complementary tool for evaluating and monitoring BM hypoplasia.